TerminatedNCT00929370

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

Medication studyAges 18–55United States

The study in practice

Understand this study

Listed age limits: 18 years to 55 years.

Listed locations: Glendale and 1 more locationSee all locations and recruitment
Study phase: Phase 1

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateJuly 2008

Recruitment status: Terminated
Enrollment listed in the registry: 34
Sponsor: GlaxoSmithKline
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT00929370
Official title: Show the full official title
A 4-Part Parallel Group, Randomized, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Repeat Doses of GSK1018921 in Healthy Volunteers and Stable Patients With Schizophrenia and to Evaluate Its Effects on Pharmacokinetics of Midazolam.

The HopeStage team will email you.

Terminated

Glendale · Bellaire

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Does this study involve medication?

Yes. The study involves medication, including Glycine Transporter-1 inhibitor.

Who can participate?

Listed age limits: 18 years to 55 years.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.